Literature DB >> 15953646

Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy.

Zulal Ozkurt1, Ilhami Kiki, Serpil Erol, Fuat Erdem, Neziha Yilmaz, Mehmet Parlak, Mehmet Gundogdu, Mehmet A Tasyaran.   

Abstract

OBJECTIVES: This study described the clinical features, factors affecting the outcome of this disease, risk factors, and efficacy of ribavirin therapy for CCHF patients in Eastern Turkey.
METHODS: Between 2002 and 2004, 60 cases admitted to our hospital were included in this study. The diagnosis was confirmed through detection of IgM by ELISA and/or genomic segment of virus by RT-PCR.
RESULTS: In multivariate analysis, farming (OR, 11.4), living in a rural area (OR, 10.05) and being bitten by tick (OR, 6.75) were determined as risk factors for CCHF. The rates of fever during hospitalization, confusion, neck stiffness, bleeding from multiple sites, and presence of petechia/ecchymosis were higher in the patients who died than in surviving ones. Additionally, the mean values of ALT, AST, LHD, CK, PTT, INR and urea were also higher, and the mean PLT count was lower in the patients who died. Mean recovery time was shorter in the cases treated with ribavirin than those of control. But, the need for blood and blood product, mean hospitalization duration, fatality rates, and hospital expenditure values were not significantly different between the group of patients treated with ribavirin and control groups.
CONCLUSIONS: In Eastern Turkey, clinical features, factors influencing outcome of the disease, and risk factors were similar to other outbreaks of CCHF. Further studies are needed for the evaluation of ribavirin therapy in CCHF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953646     DOI: 10.1016/j.jinf.2005.05.003

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  29 in total

1.  Evaluation of cases with a preliminary diagnosis of Crimean- Congo hemorrhagic fever and comparison of characteristics in patients admitted to a secondary care hospital in Kastamonu, Turkey.

Authors:  Hüseyin Can Hekimoğlu; Neşe Ateş Demirci
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

2.  The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising.

Authors:  N Tasdelen Fisgin; O Ergonul; L Doganci; N Tulek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-03-20       Impact factor: 3.267

3.  Alterations of serum brain type natriuretic peptide (BNP) in patients with Crimean-Congo hemorrhagic fever.

Authors:  Elif Bilge Uysal; Enver Sancakdar; Ayşe Şeker; Köksal Deveci; Nevin Tuzcu; Hekim Karapınar
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  Crimean-Congo hemorrhagic fever: Risk factors and control measures for the infection abatement.

Authors:  Saadia Aslam; Muhammad Shahzad Latif; Muhammad Daud; Zia Ur Rahman; Bushra Tabassum; Muhammad Sohail Riaz; Anwar Khan; Muhammad Tariq; Tayyab Husnain
Journal:  Biomed Rep       Date:  2015-11-18

5.  Can serum ferritin level predict disease severity in patients with crimean-congo hemorrhagic Fever?

Authors:  Maliheh Metanat; Batool Sharifi-Mood; Mehdi Tabatabaei; Mohammad Sarraf-Shirazi
Journal:  Eurasian J Med       Date:  2013-06

Review 6.  Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis.

Authors:  Karla Soares-Weiser; Sherine Thomas; Gail Thomson; Paul Garner
Journal:  BMC Infect Dis       Date:  2010-07-13       Impact factor: 3.090

7.  Evaluation of patients with Crimean-Congo hemorrhagic fever in Bolu, Turkey.

Authors:  A Duran; A Küçükbayrak; T Ocak; N I Hakyemez; T Taþ; M Karadađ; Z F Mengelođlu
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

8.  Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF).

Authors:  M Bakır; M G Gözel; I Köksal; Z Aşık; Ö Günal; H Yılmaz; A But; G Yılmaz; A Engin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-12       Impact factor: 3.267

Review 9.  Crimean-Congo hemorrhagic fever: an overview.

Authors:  Serkan Oncü
Journal:  Virol Sin       Date:  2013-07-22       Impact factor: 4.327

10.  Direct healthcare costs for patients hospitalized with Crimean-Congo haemorrhagic fever can be predicted by a clinical illness severity scoring system.

Authors:  Ilkay Bozkurt; Mustafa Sunbul; Hava Yilmaz; Saban Esen; Hakan Leblebicioglu; Nicholas J Beeching
Journal:  Pathog Glob Health       Date:  2016-02-25       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.